Company news
Quantum Cyber N.V. news in 2022
Quantum Cyber N.V.'s news releases, calls and decks from 2022, newest first.
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
December 19, 2022
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
December 5, 2022
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 28, 2022
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
November 14, 2022
Mainz Biomed Provides Third Quarter 2022 Update
November 1, 2022
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
September 27, 2022
Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
September 19, 2022
Mainz Biomed Reports First Half 2022 Financial Results
September 6, 2022
Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
August 15, 2022
Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development
August 2, 2022
Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board
July 18, 2022
Mainz Biomed Today to Provide Corporate Update for First Half of 2022
July 11, 2022
Mainz Biomed Provides Corporate Update for First Half of 2022
July 4, 2022
Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
June 27, 2022
Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission
June 13, 2022
Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance
May 31, 2022
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
May 18, 2022
Mainz Biomed to Host Key Opinion Leader Event at DDW 2022
May 8, 2022
Mainz Biomed Provides Product Development Update on PancAlert
May 4, 2022
Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer
April 25, 2022
Mainz Biomed Announces First Quarter 2022 Results
April 11, 2022
Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert’s Pivotal Clinical Trial
March 30, 2022
Mainz Biomed to Ring Nasdaq Stock Market Closing Bell
March 20, 2022
Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study
March 16, 2022
Mainz Biomed Announces Year End 2021 Results
March 8, 2022
Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month
March 1, 2022
Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert
February 22, 2022
Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach
February 13, 2022
Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board
February 8, 2022
Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert
February 3, 2022
Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 27, 2022
Mainz Biomed Appoints Steve Quinn as VP Business Development
January 26, 2022
Mainz Biomed Announces Pricing of Follow-on Offering
January 25, 2022
Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert
January 18, 2022
Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board
January 11, 2022
Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers
January 4, 2022